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A B S T R A C T
Background: Most practice guidelines recommend maintenance antidepressant treatment for recurrent
major depressive disorder. However, the degree to which such guidance is actually followed in primary
health care has remained obscure. We investigated the provision of maintenance antidepressant
treatment within a representative primary care ﬁve-year cohort study.
Methods: In the Vantaa Primary Care Depression Study, a stratiﬁed random sample of 1119 adult patients
was screened for depression using the Prime-MD. Depressive and comorbid psychiatric disorders were
diagnosed using SCID-I/P and SCID-II interviews. Of the 137 patients with depressive disorders, 82%
completed the prospective ﬁve-year follow-up. A graphic life chart enabling evaluation of the
longitudinal course of episodes plus duration of pharmacotherapies was used. In accordance with
national guidelines, an indication for maintenance treatment was deﬁned to exist after three or more
lifetime major depressive episodes (MDEs); maintenance treatment was to commence four months after
onset of full remission.
Results: Of the cohort patients, 34% (46/137) had three or more lifetime MDEs, thus indicating the
requirement for maintenance pharmacotherapy. Of these, half (54%, 25/46) received maintenance
treatment, for only 29% (489/1670) of the months indicated.
Conclusions: In this cohort of depressed primary care patients, half of patients with indications for
maintenance treatment actually received it, and only for a fraction of the time indicated. Antidepressant
maintenance treatment for the prevention of recurrences is unlikely to be subject to large-scale
actualization as recommended, which may signiﬁcantly undermine the potential public health beneﬁts
of treatment.
 2016 Elsevier Masson SAS. All rights reserved.
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Depressive disorders are mostly evaluated and treated in
primary care settings, where chronic and recurrent depressions
are common [1]. Most practice guidelines produced by national
health care organizations or professional societies recommend
antidepressant maintenance pharmacotherapy for patients with
three or more major depressive episodes (MDEs) [2–5]. However,
the degree to which such guidance is actually followed in primary
care has remained obscure. Although registry-based studies [6,7]
indicate a large proportion of patients receiving long-term* Corresponding author. Department of Psychiatry, Faculty of Medicine,
University of Helsinki, P.O. Box 22, 00014 Helsinki, Finland.
Tel.: +358 9 471 63728; fax: +358 9 471 63735.
E-mail address: erkki.isometsa@hus.ﬁ (E. Isometsa¨).
http://dx.doi.org/10.1016/j.eurpsy.2016.10.010
0924-9338/ 2016 Elsevier Masson SAS. All rights reserved.antidepressant medication, indications for patients’ long-term
treatment remain unclear. Long-term antidepressant treatment
may reﬂect the chronicity of depression, nonspeciﬁc long-term use
of antidepressants, deliberate maintenance treatment, or antide-
pressant treatment for other indications. A major methodological
obstacle for clinical-epidemiological studies in this ﬁeld is that
evaluating continuity and adequacy of maintenance treatment of
depression necessitates both determining treatment phases (acute,
continuation or maintenance) using labor-intensive life-chart
methodology, and concurrently incorporating accurate data on
the temporal course of pharmacological treatment. Therefore, such
studies are scarce. In our previous life-chart-based study from
secondary care regional psychiatric services, we documented major
shortcomings in the implementation of maintenance treatment [8].
To our knowledge, no primary care study has examined how
recommendations for antidepressant maintenance treatment are
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predictors, and roles of attitudes and adherence in a naturalistic
prospective long-term Finnish cohort of primary care patients with
depressive disorders.
2. Material and methods
2.1. Patients and procedures
The methodology of the Vantaa Primary Care Depression Study
(PC-VDS) has been published in detail elsewhere [9,10]. In brief,
based on stratiﬁed sampling, altogether 373 of 1119 general
practitioners’ (GP) patients aged 20–69 screened with the PRIME-
MD had a positive screen for depression. The presence of at least
one core symptom of major depressive disorder (MDD) according
to the Structured Clinical Interview for DSM-IV Axis I Disorders
(SCID-I/P) [11] was conﬁrmed by telephone. All of the 175 poten-
tially eligible patients were interviewed face-to-face using the
SCID-I/P with psychotic screen. Inclusion criteria were current (1)
MDD, (2) dysthymia, (3) subsyndromal MDD with two to four
depressive symptoms (minimum one core symptom) and lifetime
MDD and (4) minor depression otherwise similar to subsyndromal
MDD, but without an MDD history. Refused (15%) and consented
patients did not differ signiﬁcantly in age or gender. The diagnostic
reliability for current depressive disorder was excellent (kap-
pa = 1.0). The PC-VDS was approved by the pertinent Ethics
Committee in 2001.
The ﬁnal sample comprised 137 patients. Current and lifetime
psychiatric disorders were assessed with SCID-I/P and SCID-II
interviews [11,12]. In addition to face-to-face interviews, observ-
er- and self-report scales and all medical and psychiatric records
were used to assess retrospective and prospective course of
depression, comorbid disorders and psychosocial and socioeco-
nomic factors. After baseline, patients were prospectively investi-
gated at 3, 6 and 18 months and 5 years [10]. The 5-year
investigation included all the same diagnostic interviews, scales
and records as at baseline. The timing and duration of episodes of
depression (MDEs and partial and full remission) and indications
for acute, continuation and maintenance antidepressant treatment
were integrated into a graphic life chart. We deﬁned maintenance
indication to exist after three or more lifetime MDEs (before or
during the follow-up) and then achieved full remission for more
than two months; treatment was to commence four months after
the onset of full remission (National Finnish Current Care Guideline
2016). We have previously reported methodology and ﬁndings
related to acute phase treatment [13].
Of the 137 patients initially included in the study, 127 (93%)
participated in the 18-month and 112 (82%) in the 5-year follow-
up. Patients remained in the cohort until they were censored due to
change of diagnosis to bipolar disorder (4%, 5/137) or death (4%, 6/
137). The ﬁnal follow-up group consisted of the 134 patients with
some follow-up information, 110 of them had had lifetime MDD.
The dropouts (18%) did not signiﬁcantly differ from participants in
terms of socio-demographic or clinical features [10].
2.2. Measures of attitudes, adherence and contacts with general
practitioners (GP)
Attitudes towards different treatments were rated very
positive, positive, neutral, negative and very negative, and
analyzed in two groups: favorable and negative. Patient adherence
to antidepressants was rated (1) regularly, (2) somewhat irregu-
larly (whether this would affect treatment goals was unknown), (3)
very irregularly (treatment did not proceed according to plan), or
(4) not at all (provided treatment could not be implemented). All
contacts with GPs concerning any health problems were totaled;the monitoring comprised all contacts where depression-related
symptoms or treatments were discussed. The primary reasons for
poor adherence were classiﬁed into patient-, GP- and organization-
related factors with a semi-structured questionnaire, based on
interviews and records.
2.3. Statistical methods
Between-group comparisons were carried out using Fisher’s
exact test, the two-sample t-test, and the Mann-Whitney or
Kruskal-Wallis tests. Logistic and linear regression models were
used to investigate associations of different variables; models were
controlled for age, gender and duration of maintenance indication,
and in the ﬁnal models, the non-signiﬁcant variables were omitted.
SPSS, version 23, was used.
3. Results
3.1. Proportion and duration of indicated and received maintenance
antidepressant treatment during the 5-year follow-up
Altogether 34% (46/137) of the cohort patients had three or
more lifetime MDEs, and thus an indication for maintenance
pharmacotherapy. Half (54%, 25/46) of them actually received it.
The most frequently prescribed antidepressants were selective
serotonin reuptake inhibitors. Characteristics of patients with an
indication of maintenance, comparing those who received it with
those who had not, are presented in Table 1.
Among the 46 patients, maintenance treatment would have
been indicated for a mean 36.3 months (median 41.8, SD 20.6, 1–
74 months). However, the mean observed duration of maintenance
treatment was 19.6 months (median 12.0, SD 18.0, 1–60 months).
It covered 29% (489/1670 months) of the time the indication was in
force (Fig. 1).
3.2. Follow-up contacts with general practitioners (GP) and
psychosocial treatments during the 5-year follow-up
During the follow-up, the patients visited GPs overall (for any
reason) for a mean of 19 times (median 13, SD  21, 0–153). The
mean number of GP contacts due to depression was 8 (median 4,
SD  12, 0–83). A fourth (24%) of the patients also sought psychiatric
care, often ambulatory. One ﬁfth (20%) were treated in psychiatric
outpatient units and one tenth (11%) received inpatient care. Some
kind of psychosocial support other than that from a GP was offered to
one third (38%); one ﬁfth (20%) actually received it.
3.3. Patients’ attitudes and adherence to antidepressant treatment
Patients’ attitudes to antidepressants were very positive in 29%,
positive in 42%, neutral in 17%, negative in 7% and very negative in
5%; to maintenance in 26%, 36%, 23%, 8% and 8%, respectively, and
for comparison, to psychotherapeutic support in 45%, 40%, 13%, 3%
and 0%. There were no statistically differences in attitudes towards
different treatments.
The patients receiving maintenance antidepressant treatment
had reportedly adhered to it regularly in 29%, moderately in 25%,
incompletely in 23% and not at all in 23% of the cases.
The reasons for poor adherence included patient-related factors
in 37%, GP-related factors in 43% and organization-related factors
in 20% of the cases. Patients-related factors included inability to
adhere, lack of motivation, negative attitudes, recovery, and
inadequate effects, side effects or costs of antidepressants. GP-
related factors included incomplete follow-up (41%), antidepres-
sant not offered (20%), inadequately small dosage (0%), dosage not
increased (10%), antidepressant not changed (3%), maintenance
Table 1
Characteristics of depressive patients with indicated maintenance antidepressant (AD) treatment in the Vantaa Primary Care Depression Study (n = 46/137).
Maintenance AD,
n = 25
No maintenance,
n = 21
Total P
n % n % n %
Socio-demographic features
Female 21 84 19 91 40 63 0.521
Married or cohabiting 8 32 12 57 20 44 0.090
Vocational education, any 17 68 16 76 33 72 0.543
Employed 15 60 7 33 22 48 0.067
Welfare beneﬁt received 10 40 3 14 13 28 0.055
Clinical features
Comorbid psychiatric disorder (any) 21 84 10 48 31 67 0.008
Axis I, any 19 76 7 33 26 57 0.005
Anxiety disorder, any 14 44 5 24 19 41 0.029
Cluster C personality disorder 12 48 4 19 16 35 0.042
Borderline personality disorder 6 24 5 24 11 24 0.988
Substance use disorder 2 8 2 10 4 9 0.857
Treatment-related factors
Positive attitude to maintenance AD 10 63 10 83 20 71 0.236
Good adherence to ADs 7 35 0 0 7 28 0.127
Organization-related reasons to shorter maintenance 9 56 4 80 13 62 0.365
Psychosocial treatment during the 5-year follow-up 17 71 2 10 19 46 < 0.001
Psychiatric care during follow-up 7 28 2 10 9 20 0.120
Mean SD Mean SD Mean SD P
Socio-demographic features
Age (years) 42.8 14.4 42.2 13.8 42.5 13.8 0.886
Clinical features
Beck depression inventory 18.9 8.7 14.5 10.2 16.9 9.6 0.121
Beck anxiety inventory 15.6 11.0 13.1 12.5 14.5 11.6 0.121
Social and Occupational Functioning Assessment Scale 60.6 10.5 57.6 10.3 59.2 10.4 0.340
Neuroticism (EPI-Q) 7.0 1.8 5.6 2.5 6.3 2.2 0.030
Number of MDEs 6.0 4.3 3.5 4.2 4.9 4.4 0.002
Time spent in MDE during 5 years (months) 15.8 14.5 6.5 10.1 11.5 13.4 0.009
Time spent in full remission (months) 35.3 18.7 46.6 18.9 40.5 19.4 0.050
Treatment-related factors
Maintenance indication duration during 5 years (month) 32.5 19.0 41.0 22.3 36.4 20.6 0.123
GP contacts due to depression 10.6 9.5 7.1 15.0 9 12.3 0.005
Fisher’s exact test, the two-sample t-test, and the Mann-Whitney or Kruskal-Wallis tests.
Fig. 1. The duration of indicated and received maintenance antidepressant
treatment estimated by survival curve during the 5-year follow-up in the
Vantaa Primary Care Depression Study.
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undetected substance abuse (4%), and inadequate communication
(11%). Organization-related factors included difﬁculties to get an
appointment, long waiting times for psychiatric care and changes
in attending personnel.
3.4. Predictors for maintenance treatment
In univariate logistic regression analyses, from baseline
variables (adjusted for age and gender), anxiety disorders, cluster
C personality disorder and neuroticism associated with received
maintenance. However, in multivariate logistic regression, only
anxiety disorders associated with prescribed maintenance treat-
ment (OR 0.251, B 1.384, P = 0.037, 95% CI 0.068–0.921). In
univariate linear regression analyses, the results were similar. In
multivariate linear regression, from baseline variables (adjusted
for age, gender and duration of maintenance indication), duration
of received maintenance associated signiﬁcantly with anxiety
disorders (B 13.571, P = 0.013, 95% CI 3.064–24.077). Of the follow-
up variables, having received psychosocial treatment associated
with more and longer maintenance pharmacotherapy.
4. Discussion
We investigated the provision of antidepressant pharmacother-
apy for recurrent depression in a screening-based, representative
K. Riihima¨ki et al. / European Psychiatry 41 (2017) 111–114114regional cohort of primary care (PC) patients with depressive
disorders. During the ﬁve-year follow-up, half of our patients with
three or more MDEs actually received maintenance antidepressant
treatment, for only a fraction of the time indicated. Despite
generally positive attitudes, only a third of even those receiving
maintenance antidepressants reported good adherence to it.
The major strength of the study was the use of a life chart, which
enabled to evaluate not only the time spent in different states of
depression (MDE and partial and full remission) but also the
durations of different treatment indications (acute, continuation
and maintenance) and all treatments received [10]. Further
strengths included the screening-based cohort from a stratiﬁed
sampling of 1119 patients, structured interviews with SCID-I/P and
SCID-II by psychiatrists and the longitudinal study design with a
ﬁve-year follow-up, and a small dropout rate. All primary and
psychiatric care records were available. Patient attitudes towards
treatment, adherence and attributed reasons for poor adherences
were investigated. The naturalistic study design reﬂects the actual
patient load of the local GPs.
Nevertheless, some limitations need to be noted. First, despite
extensive screening of a large number of patients [9], the size of the
cohort (n = 137) remained moderate, and number of patients with
an indication for maintenance antidepressant treatment (n = 46)
still smaller. This renders the study somewhat vulnerable to type II
errors and risk of spurious ﬁndings. Second, because our study was
performed between 2002–2007, generalisability of ﬁndings to
current settings remains uncertain. Preceding and at the time of
prospective cohort data collection, the GPs were educated about
depression. This included use and indications of antidepressant
maintenance treatment, recommended by the ﬁrst national
Finnish Current Guideline for depression published in 2004. Third,
primary care records may be quite concise, e.g. offered treatment
may not have been recorded in cases a patient refused, which could
lead to underestimates of treatments offered. Fourth, the attitudes
of the attending GPs were not evaluated. Fifth, our analyses focus
on whether or not the patients were prescribed antidepressants
during a period during which this, based on the deﬁnition, was
indicated as maintenance treatment. The actual treatment decision
may or may not have been based on such considerations. Finally,
generalisability of our ﬁndings needs to be conﬁrmed by
replicating them in other representative studies in other settings.
To our knowledge, no other primary care study has reported
results for provision and continuity of maintenance antidepressant
pharmacotherapy. In an analysis of the Dutch longitudinal
epidemiological NESDA study data, Piek et al. [14] approximated
indications and provision of maintenance antidepressant among
primary care attenders, ﬁnding characteristics of those receiving
long-term antidepressant treatment not fully concordant with
national guidelines. Our ﬁndings replicate those from an earlier
similar life-chart-based study [8] conducted in the same area in
psychiatric settings. Knowledge of predictors might be helpful for
improving care, but when analyzing them, it is difﬁcult to
differentiate causes from consequences. Due to confounding by
indication, observed predictors may in fact predict only chronic
course of depression. Finding longer times of maintenance
associated with more psychosocial support is potentially of
interest. However, psychosocial support could contribute to
antidepressant-adherence or vice versa; achieving full remission
and thus an indication for maintenance antidepressants, or
patients suffering from chronic or recurrent depression or having
positive attitudes to treatment may receive more kinds of
treatments.While not systematically evaluated, our strong impression from
the patient interviews and records was, that GPs rarely conceptu-
alized or discussed continuing antidepressant treatment in terms of
preventing depressive recurrences, or phases of treatment. Primary
care patients contact their GPs for many different, often multiple
somatic and psychiatric reasons. Antidepressants were often
prescribed along while treating other issues, and patient records
may thus have remained incomplete. There were few, if any,
deliberate recorded treatment decisions of maintenance treatment.
5. Conclusions
In this representative Finnish cohort of depressed primary care
patients, we found that half of the patients with indications for
maintenance treatment actually received it, and only for a fraction
of the time indicated. We expect that antidepressant maintenance
treatment for the prevention of recurrences is unlikely to actualize
on as large a scale as recommended, which may signiﬁcantly
undermine the potential public health beneﬁts of treatment.
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